Navigation Links
Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call

ROCKVILLE, Md., July 31 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will report its 2009 second quarter financial results in a press release to be issued after 8:00 a.m. Eastern Time on Friday, August 7, 2009. The Company will hold an investor conference call to discuss its financial results at 10:00 a.m. Eastern Time on Friday, August 7, 2009. The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management. A question and answer session will follow the financial results overview. The dial-in number for the conference call is 1 (866) 206-5917 (International: 1 (703) 639-1106.

A live audio webcast of the conference call will be available at under Investors/Events. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available on the website for 90 days after the call and a replay of the conference call will also be available by telephone beginning August 7th, 2009 at 1:00 pm through August 12, 2009 at 11:59pm. To access the replay, dial 1 (888) 266 2081 and enter pass code 1366728.

About Novavax, Inc.

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at and in the Company's various filings with the Securities and Exchange Commission.

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
2. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
3. Novavax Announces Repayment of $5 Million of Convertible Debt
4. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
5. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
6. Novavax Appoints Stanley Erck to Board of Directors
7. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
8. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
9. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
10. Novavax Reports First Quarter 2009 Financial Results
11. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
Post Your Comments:
(Date:6/27/2016)... ... 27, 2016 , ... Cancer experts from Austria, Hungary, Switzerland, ... a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just ... now. , Biomarkers are components in the blood, tissue or body fluids ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
Breaking Biology News(10 mins):